Diagnosis and management of eosinophilic asthma: A US perspective

Journal of Asthma and Allergy

Volumn , Issue 7, 2014, Pages 53-65

  Walford, Hannah H ^a   Doherty, Taylor A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allergy; Asthma; Eosinophil; IL 13; IL 4; Th2

Indexed keywords

ALTRAKINCEPT; BENRALIZUMAB; DUPILUMAB; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5; LEBRIKIZUMAB; MEPOLIZUMAB; NITRIC OXIDE; OMALIZUMAB; PASCOLIZUMAB; PITRAKINRA; PLACEBO; RESLIZUMAB; TRANSCRIPTION FACTOR RUNX2;

ASTHMA; BIOLOGICAL THERAPY; BREATH ANALYSIS; CLINICAL FEATURE; DRUG RESPONSE; DRUG TARGETING; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIC ASTHMA; HUMAN; IMMUNOPATHOGENESIS; MANAGED CARE; NONHUMAN; PHENOTYPE; REVIEW; TREATMENT OUTCOME; UNITED STATES;

EID: 84903604618     PISSN: 11786965     EISSN: None     Source Type: Journal    
DOI: 10.2147/JAA.S39119     Document Type: Review

References (120)

1. Bateman ED, Boushey HA, Bousquet J, et al; GOAL Inverstigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med. 2004;170(8):836-844.
2. Centers for Disease Control and Prevention. Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001-2009. MMWR Morb Mortal Wkly Rep. 2011;60(17): 547-552.
3. Cisternas MG, Blanc PD, Yen IH, etal. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003;111:1212-1218.
4. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368:804-813.
5. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372: 1107-1119.
6. Lotvall J, Akdis CA, Bacharier LB, etal. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127:355-360.
7. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11:54-61.
8. Wenzel SE, Schwartz LB, Langmack EL, etal. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160:1001-1008.
9. Amelink M, de Groot JC, de Nijs SB, etal. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol. 2013;132:336-341.
10. Houston JC, De Navasquez S, Trounce JR. A clinical and pathological study of fatal cases of status asthmaticus. Thorax. 1953;8:207-213.
11. Bousquet J, Chanez P, Lacoste JY, etal. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323:1033-1039.
12. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med. 2000;161:64-72.
13. Deykin A, Lazarus SC, Fahy JV, etal. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol. 2005;115:720-727.
14. Meijer RJ, Postma DS, Kauffman HF, Arends LR, Koeter GH, Kerstjens HA. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy. 2002;32:1096-1103.
15. Berry M, Morgan A, Shaw DE, etal. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax. 2007;62:1043-1049.
16. Haldar P, Brightling CE, Hargadon B, etal. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360: 973-984.
17. Nair P, Pizzichini MM, Kjarsgaard M, etal. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985-993.
18. Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol. 2009;71:489-507.
19. Barrett NA, Austen KF. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity. 2009;31:425-437.
20. Doherty T, Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol. 2007;19:676-680.
21. Garty BZ, Kosman E, Ganor E, etal. Emergency room visits of asthmatic children, relation to air pollution, weather, and airborne allergens. Ann Allergy Asthma Immunol. 1998;81:563-570.
22. D'Amato G, Cecchi L, Liccardi G. Thunderstorm-related asthma: not only grass pollen and spores. J Allergy Clin Immunol. 2008;121: 537-538.
23. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med. 2012;18:673-683.
24. Lee HC, Headley MB, Loo YM, etal. Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. J Allergy Clin Immunol. 2012;130:1187-1196. e5.
25. Ziegler SF. Thymic stromal lymphopoietin and allergic disease. J Allergy Clin Immunol. 2012;130:845-852.
26. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118:3546-3556.
27. Wardlaw AJ, Brightling C, Green R, Woltmann G, Pavord I. Eosinophils in asthma and other allergic diseases. Br Med Bull. 2000; 56:985-1003.
28. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med. 1995;182: 1169-1174.
29. Zietkowski Z, Tomasiak MM, Skiepko R, Bodzenta-Lukaszyk A. RANTES in exhaled breath condensate of stable and unstable asthma patients. Respir Med. 2008;102:1198-1202.
30. Broide DH, Paine MM, Firestein GS. Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest. 1992;90: 1414-1424.
31. Broide DH, Firestein GS. Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization. J Clin Invest. 1991;88: 1048-1053.
32. Davies D, Larbi K, Allen A, etal. VCAM-1 contributes to rapid eosinophil accumulation induced by the chemoattractants PAF and LTB4: evidence for basal expression of functional VCAM-1 in rat skin. Immunology. 1999;97:150-158.
33. Stirling RG, van Rensen EL, Barnes PJ, Chung KF. Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med. 2001;164: 1403-1409.
34. Cho JY, Miller M, Baek KJ, etal. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest. 2004;113:551-560.
35. Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc Am Thorac Soc. 2009;6:256-259.
36. Green RH, Brightling CE, McKenna S, etal. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715-1721.
37. Woodruff PG, Khashayar R, Lazarus SC, etal. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol. 2001;108:753-758.
38. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med. 2000;161:9-16.
39. Porsbjerg C, Lund TK, Pedersen L, Backer V. Inflammatory subtypes in asthma are related to airway hyperresponsiveness to mannitol and exhaled NO. J Asthma. 2009;46:606-612.
40. Crimi E, Spanevello A, Neri M, Ind PW, Rossi GA, Brusasco V. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am J Respir Crit Care Med. 1998;157:4-9.
41. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol. 2004;113:101-108.
42. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med. 2004;170:601-605.
43. Thomson NC, Chaudhuri R. Why is eosinophilic bronchitis not asthma? Am J Respir Crit Care Med. 2004;170:4-5.
44. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002;346:1699-1705.
45. Kanazawa H, Nomura S, Yoshikawa J. Role of microvascular permeability on physiologic differences in asthma and eosinophilic bronchitis. Am J Respir Crit Care Med. 2004;169:1125-1130.
46. Frick WE, Sedgwick JB, Busse WW. The appearance of hypodense eosinophils in antigen-dependent late phase asthma. Am Rev Respir Dis. 1989;139:1401-1406.
47. Ulrik CS. Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma. Clin Exp Allergy. 1995;25:820-827.
48. Hastie AT, Moore WC, Li H, etal. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol. 2013;132:72-80.
49. D'Silva L, Cook RJ, Allen CJ, Hargreave FE, Parameswaran K. Changing pattern of sputum cell counts during successive exacerbations of airway disease. Respir Med. 2007;101:2217-2220.
50. Good JT Jr, Kolakowski CA, Groshong SD, Murphy JR, Martin RJ. Refractory asthma: importance of bronchoscopy to identify phenotypes and direct therapy. Chest. 2011;141:599-606.
51. Silkoff PE, Lent AM, Busacker AA, etal. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol. 2005;116:1249-1255.
52. Mahr TA, Malka J, Spahn JD. Inflammometry in pediatric asthma: a review of fractional exhaled nitric oxide in clinical practice. Allergy Asthma Proc. 2013;34:210-219.
53. Barnes PJ, Dweik RA, Gelb AF, etal. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest. 2010;138:682-692.
54. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005;352:2163-2173.
55. Tseliou E, Bessa V, Hillas G, etal. Exhaled nitric oxide and exhaled breath condensate pH in severe refractory asthma. Chest. 2010;138: 107-113.
56. Blanchard C, Mingler MK, McBride M, etal. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol. 2008;1:289-296.
57. Ouyang G, Liu M, Ruan K, Song G, Mao Y, Bao S. Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett. 2009;281:213-219.
58. Jia G, Erickson RW, Choy DF, etal. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130:647-654. e10.
59. Corren J, Lemanske RF, Hanania NA, etal. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088-1098.
60. Masuoka M, Shiraishi H, Ohta S, etal. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012;122:2590-2600.
61. Gordon ED, Sidhu SS, Wang ZE, etal. A protective role for periostin and TGF-beta in IgE-mediated allergy and airway hyperresponsiveness. Clin Exp Allergy. 2012;42:144-155.
62. Kulkarni NS, Hollins F, Sutcliffe A, etal. Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma. J Allergy Clin Immunol. 2010;126:61-69. e3.
63. Barnes PJ. Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol. 2012;129:48-59.
64. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol. 2002;109:649-657.
65. Maneechotesuwan K, Xin Y, Ito K, etal. Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J Immunol. 2007;178:2491-2498.
66. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 2007;1773: 1358-1375.
67. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373:1905-1917.
68. Mizue Y, Ghani S, Leng L, etal. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci U S A. 2005;102:14410-14415.
69. Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012;11:958-972.
70. Saini SS, MacGlashan DW Jr, Sterbinsky SA, etal. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999;162:5624-5630.
71. Humbert M, Beasley R, Ayres J, etal. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309-316.
72. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59:701-708.
73. Vignola AM, Humbert M, Bousquet J, etal. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709-717.
74. Busse W, Corren J, Lanier BQ, etal. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184-190.
75. Soler M, Matz J, Townley R, etal. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254-261.
76. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91:154-159.
77. Holgate ST, Chuchalin AG, Hebert J, etal. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34:632-638.
78. Bousquet J, Rabe K, Humbert M, etal. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101:1483-1492.
79. Noga O, Hanf G, Brachmann I, etal. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006;117:1493-1499.
80. Djukanovic R, Wilson SJ, Kraft M, etal. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170:583-593.
81. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol. 2003;131:46-52.
82. Milgrom H, Fick RB Jr, Su JQ, etal. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341:1966-1973.
83. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115: 459-465.
84. Chand HS, Schuyler M, Joste N, etal. Anti-IgE therapy results in decreased myeloid dendritic cells in asthmatic airways. J Allergy Clin Immunol. 2010;125:1157-1158. e5.
85. Kaya H, Gumus S, Ucar E, etal. Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia. Chest. 2012;142:513-516.
86. Hamid Q, Azzawi M, Ying S, etal. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest. 1991;87:1541-1546.
87. Humbert M, Corrigan CJ, Kimmitt P, Till SJ, Kay AB, Durham SR. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med. 1997;156: 704-708.
88. Garlisi CG, Kung TT, Wang P, etal. Effects of chronic anti-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am J Respir Cell Mol Biol. 1999;20:248-255.
89. Gnanakumaran G, Babu KS. Technology evaluation: mepolizumab, GlaxoSmithKline. Curr Opin Mol Ther. 2003;5:321-325.
90. Menzies-Gow A, Flood-Page P, Sehmi R, etal. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol. 2003;111:714-719.
91. Kips JC, O'Connor BJ, Langley SJ, etal. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167:1655-1659.
92. Leckie MJ, ten Brinke A, Khan J, etal. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356:2144-2148.
93. Flood-Page P, Swenson C, Faiferman I, etal. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176:1062-1071.
94. Castro M, Mathur S, Hargreave F, etal. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125-1132.
95. Busse WW, Katial R, Gossage D, etal. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010;125:1237-1244. e2.
96. Laviolette M, Gossage DL, Gauvreau G, etal. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132:1086-1096. e5.
97. Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol. 2012;130: 829-842.
98. Hart TK, Blackburn MN, Brigham-Burke M, etal. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002;130:93-100.
99. Henderson WR Jr, Chi EY, Maliszewski CR. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J Immunol. 2000;164:1086-1095.
100. Borish LC, Nelson HS, Corren J, etal. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001;107:963-970.
101. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370:1422-1431.
102. Wenzel S, Ford L, Pearlman D, etal. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368: 2455-2466.
103. Pope SM, Brandt EB, Mishra A, etal. IL-13 induces eosinophil recruitment into the lung by an IL-5-and eotaxin-dependent mechanism. J Allergy Clin Immunol. 2001;108:594-601.
104. Spahn JD, Szefler SJ, Surs W, Doherty DE, Nimmagadda SR, Leung DY. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol. 1996;157:2654-2659.
105. Yang G, Volk A, Petley T, etal. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine. 2004;28:224-232.
106. Bree A, Schlerman FJ, Wadanoli M, etal. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol. 2007;119:1251-1257.
107. Gauvreau GM, Boulet LP, Cockcroft DW, etal. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2011;183:1007-1014.
108. Piper E, Brightling C, Niven R, etal. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41:330-338.
109. Tamachi T, Maezawa Y, Ikeda K, etal. IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. J Allergy Clin Immunol. 2006;118:606-614.
110. Fujita J, Kawaguchi M, Kokubu F, etal. Interleukin-33 induces interleukin-17F in bronchial epithelial cells. Allergy. 2012;67: 744-750.
111. Shi L, Leu SW, Xu F, etal. Local blockade of TSLP receptor alleviated allergic disease by regulating airway dendritic cells. Clin Immunol. 2008;129:202-210.
112. Amgen. Double-blind, Multiple Dose Study in Subjects With Mild Atopic Asthma. Available from: http://clinicaltrials.gov/show/NCT01405963. NLM identifier: NCT01405963. Accessed February 3, 2014.
113. Gauvreau GM, Boulet LP, Cockcroft DW, etal. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med. 2008;177:952-958.
114. Krinner EM, Raum T, Petsch S, etal. A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. Mol Immunol. 2007;44:916-925.
115. Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther. 2012;135:327-336.
116. Wenzel SE, Barnes PJ, Bleecker ER, etal. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179:549-558.
117. Holgate ST, Noonan M, Chanez P, etal. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J. 2011;37:1352-1359.
118. Castro M, Musani AI, Mayse ML, Shargill NS. Bronchial thermoplasty: a novel technique in the treatment of severe asthma. Ther Adv Respir Dis. 2010;4:101-116.
119. Castro M, Rubin AS, Laviolette M, etal. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2012;181:116-124.
120. Thomson NC, Rubin AS, Niven RM, etal. Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. BMC Pulm Med. 2011;11:8.